Total thyroidectomy versus limited thyroidectomy for isthmic papillary thyroid carcinoma: a systematic review and meta-analysis of oncologic outcomes and surgical morbidity.

J Endocrinol InvestAug 17, 2026 (epub)

Ziliang Ding, Yukun Wei, Xiaoxiao Yao et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis compared oncologic outcomes and surgical complications after total versus limited thyroidectomy for isthmic papillary thyroid carcinoma. It included eight retrospective cohort studies with 1,285 patients. Recurrence rates were not significantly different (limited thyroidectomy: 6.61% vs. total thyroidectomy: 4.07%; pooled RR = 1.40, 95% CI: 0.79-2.47, P = 0.25), while limited thyroidectomy was associated with fewer overall complications (RR = 0.39, 95% CI: 0.30-0.50, P < 0.00001). The authors caution that these findings do not establish oncologic equivalence.

Key findings

  • Recurrence was 6.61% after limited thyroidectomy and 4.07% after total thyroidectomy; pooled RR = 1.40, 95% CI: 0.79-2.47, P = 0.25.
  • Limited thyroidectomy was associated with fewer overall complications (RR = 0.39, 95% CI: 0.30-0.50, P < 0.00001).
  • Limited thyroidectomy was associated with lower risks of transient complications (RR = 0.39), parathyroid dysfunction (RR = 0.30), and hoarseness (RR = 0.44).

Why it matters

The findings highlight a potential trade-off in surgical extent for isthmic papillary thyroid carcinoma: limited surgery was associated with fewer complications, while the available studies did not show a statistically significant recurrence difference. Because the evidence comes from retrospective cohorts and does not establish oncologic equivalence, recurrence results should be interpreted cautiously rather than as proof that the procedures provide equivalent cancer control.

What to keep in mind

Evidence was based on retrospective cohorts, and the authors describe it as insufficient to establish oncologic equivalence. They call for prospective studies with standardized outcome definitions and extended follow-up.

Source

Published in J Endocrinol Invest. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.